{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:04:36Z","timestamp":1770822276937,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,9,6]],"date-time":"2005-09-06T00:00:00Z","timestamp":1125964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Polycythaemia vera (PV) is closely associated with both an acquired activating mutation of the <jats:italic>JAK2<\/jats:italic> tyrosine kinase (<jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup>) in granulocyte\u2010derived DNA and increased granulocyte polycythaemia rubra vera\u20101 (<jats:italic>PRV\u20101<\/jats:italic>) expression. In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> and quantitative measurement of granulocyte <jats:italic>PRV\u20101<\/jats:italic> expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers. The respective overall (homozygous) <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> mutational frequencies were 95% (26%), 55% (0%), 30% (0%), 0% and 0%. The corresponding figures for increased <jats:italic>PRV\u20101<\/jats:italic> expression were 89%, 18%, 20%, 21% and 9%. In patients with either ET or AMM, the likelihood of detecting <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> was significantly higher in the presence of an increased <jats:italic>PRV\u20101<\/jats:italic> expression (83% vs. 38%; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b705). Similarly, in patients with PV, homozygous as compared with heterozygous <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> correlated with higher levels of <jats:italic>PRV\u20101<\/jats:italic> expression (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b711). The present study suggests an allele dose\u2010dependent effect of <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> on granulocyte <jats:italic>PRV\u20101<\/jats:italic> expression. However, compared with the <jats:italic>PRV\u20101<\/jats:italic> assay, mutation screening for <jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V<\/jats:italic>617<jats:italic>F<\/jats:italic><\/jats:sup> displayed greater accuracy in distinguishing PV from SP.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05743.x","type":"journal-article","created":{"date-parts":[[2005,9,6]],"date-time":"2005-09-06T07:51:36Z","timestamp":1125993096000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Concomitant neutrophil <i>JAK2<\/i><sup>V617F<\/sup> mutation screening and <i>PRV\u20101<\/i> expression analysis in myeloproliferative disorders and secondary polycythaemia"],"prefix":"10.1111","volume":"131","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shireen","family":"Sirhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin\u2010Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra P.","family":"Wolanskyj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. G.","family":"Gilliland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.2.1058"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3502"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1515"},{"key":"e_1_2_5_6_1","volume-title":"WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1800"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1320"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0919"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05149.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0744"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2287"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb04554.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802263380903"},{"key":"e_1_2_5_18_1","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz P.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05098.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(87)90008-7"},{"key":"e_1_2_5_21_1","first-page":"406","article-title":"Neutrophil polycythemia rubra vera\u20101 expression in classic and atypical myeloproliferative disorders and laboratory correlates","volume":"90","author":"Sirhan S.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1183"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.771"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3505"},{"key":"e_1_2_5_25_1","article-title":"Is homozygosity for JAK2 V617F in myeloproliferative disorders a time\u2010acquired phenomenon?","author":"Tefferi A.","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2569"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05743.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05743.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:16:53Z","timestamp":1697419013000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05743.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05743.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05743.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,30]]},"assertion":[{"value":"2005-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}